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Background: Idiopathic pulmonary fibrosis (IPF) is a disease with a poor prognosis. Although the median survival is
3 years, the clinical course varies to a large extent among IPF patients. To date, there has been no definitive
prognostic marker. Extracellular vesicles (EVs) are known to hold nucleic acid, including microRNAs, and to regulate
gene expression in the recipient cells. Moreover, EVs have been shown to express distinct surface proteins or
enveloped microRNAs depending on the parent cell or pathological condition. We aimed to identify serum EV
microRNAs that would be prognostic for IPF.
Methods: To determine target microRNAs in IPF, we measured serum EV microRNA expression profiles using
microRNA PCR arrays in a bleomycin mouse model and validated the microRNAs in additional mice using RT-PCR.
Secondly, we enrolled 41 IPF patients and conducted a 30-month prospective cohort study. Expression of serum EV
miR-21-5p was normalized by dividing by the EV amount. The relative amount of EVs was measured using the
ExoScreen method. We calculated the correlations between baseline serum EV miR-21-5p expression and other
clinical variables. Furthermore, we determined if serum EV miR-21-5p can predict mortality during 30 months using
the Cox hazard model. According to the median level, we divided the IPF patients into two groups. Then we
compared the survival rate during 30 months between the two groups using the Kaplan-Meier method.
Results: Serum EV miR-21-5p was elevated in both the acute inflammatory phase (day 7) and the chronic fibrotic
phase (day 28) in the mouse model. In the clinical setting, serum EV miR-21-5p was significantly higher in IPF
patients than in healthy control subjects. The baseline serum EV miR-21-5p was correlated with the rate of decline
in vital capacity over 6 months. Furthermore, serum EV miR-21-5p was independently associated with mortality
during the following 30 months, even after adjustment for other variables. In the survival analysis, IPF patients
whose baseline serum EV miR-21-5p was high had a significantly poorer prognosis over 30 months.
Conclusions: Our results suggest that serum EV miR-21-5p has potential as a prognostic biomarker for IPF.
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Idiopathic pulmonary fibrosis (IPF) is a chronic and pro-
gressive lung disease for which no treatment is capable
of providing a complete cure [1–3]. The median survival
for IPF patients from the time of diagnosis is approxi-
mately 3 years [3]. Recently, new therapeutic targets for
IPF have been identified, and some of the proposed
therapies are expected to slow its progression [2]. IPF
patients differ in terms of the disease progression rate
and prognosis, complicating the prediction of survival.
The identification of prognostic predictors for IPF is im-
portant for determining who requires the most intensive
therapies.
MicroRNAs are 22-nucleotide-long non-coding RNAs
that function in the translational repression or degrad-
ation of target mRNA [4]. MicroRNAs have been shown
to affect physiological and pathological conditions, includ-
ing lung disease [5]. A recent investigation of fibrotic lung
diseases showed that the expression levels of several
microRNAs were significantly altered in fibrotic lungs,
suggesting that microRNAs contribute to the develop-
ment and progression of fibrotic lung diseases [5]. There-
fore, microRNAs have received considerable attention as
potential therapeutic targets in IPF, as well.
Exosomes are one of the major components of extra-
cellular vesicles (EVs) [6]. Recently, EVs, including
exosomes, have been considered as novel tools for inter-
cellular communication because EVs contain various
proteins and nucleic acids including microRNAs [7].
MicroRNAs in EVs can be transferred to target cells to
regulate gene expression and cell function [8–10]. EVs
and enveloped microRNAs have been shown to function
in physiological and pathological conditions [11–15].
EVs and enveloped microRNAs within biological fluids
(e.g., circulating blood) have also attracted attention as
novel biomarkers of diseases such as cancer because the
components and secretion dynamics of EVs vary accord-
ing to their cellular origin and environment [16, 17].
In this study, we explored the possibility that micro-
RNAs of serum EVs changed during lung fibrosis and
could serve as prognostic biomarkers of IPF. We exam-
ined the levels of serum EV microRNAs in a mouse
model of lung fibrosis via quantitative PCR array, which
revealed that miR-21-5p was significantly increased in
serum EVs of the mouse model. Accordingly, we evalu-
ated the levels of miR-21-5p in serum EVs (serum EV
miR-21-5p) after adjusting for difference in the quantity
of serum EVs among IPF patients.
Methods
Reagents
Total Exosome Isolation reagent (Thermo Fisher
Scientific, Waltham, MA, USA) was used for EV
purification from serum. The miRNeasy Mini Kit andSyn-cel-miR-39-3p miScript miRNA Mimic for serum EV
RNA purification was purchased from QIAGEN (Hilden,
Germany). The following antibodies were used for
ExoScreen detection of EVs; biotin-conjugated anti-
mouse CD9 (clone MZ3, Biolegend, San Diego, CA,
USA), anti-mouse CD9 (clone MZ3, Biolegend), and
anti-human CD9 (clone 12A12, Shionogi & Co., LTD,
Osaka, Japan). ChromaLink™ Biotin Labelling Kit
(Solulink, Inc., San Diego, CA, USA) was used for
biotinylation of anti-human CD9 antibody. AlphaLISA
reagents (PerkinElmer, Waltham, MA, USA) for ExoScreen
included AlphaScreen Streptavidin Donor Beads, unconju-
gated AlphaLISA Acceptor Beads and AlphaLISA Universal
Buffer. Conjugation of AlphaLISA Acceptor Beads to
anti-human or -mouse CD9 antibodies was performed
according to the manufacturer’s protocol.
Cell cultures
A mouse lung cancer cell line (Lewis lung carcinoma
(LLC)) and a mouse mesenchymal cell line (KUM-10)
were obtained from RIKEN Cell Bank, Ibaraki, Japan.
LLC and KUM-10 were cultured in DMEM with
10 % heat-inactivated fetal bovine serum (FBS) and an
antibiotic-antimycotic solution (Thermo Fisher Scientific)
at 37 °C in 5 % CO2.
Preparation of conditioned media and EVs in media
The cells were washed with phosphate-buffered saline
(PBS), and the culture medium was replaced with ad-
vanced Dulbecco’s Modified Eagle Medium for LLC and
KUM-10 cells. After incubation for 48 h, the conditioned
media were collected and centrifuged at 2000 g for
10 min at 4 °C. To thoroughly remove cellular debris,
the supernatant was filtered through a 0.22 μm filter
(EMD Millipore, Billerica, MA, USA). To prepare EVs,
the conditioned media were ultracentrifuged at 110,000 g
for 70 min at 4 °C. The pellets were washed with 11 mL of
PBS, ultracentrifuged at 110,000 g for 70 min at 4 °C and
resuspended in PBS. The protein content of the putative
EV fraction was measured using a BCA protein assay
(Thermo Fisher Scientific).
ExoScreen assay
The detailed principle and analytical methods were
presented in a previous report [18]. Briefly, a 96-well
half-area plate was filled with 5 μL of sample, 5 nM
biotinylated antibodies and 50 μg/mL AlphaLISA ac-
ceptor bead-conjugated antibodies against mouse or
human CD9 in the universal buffer. The volume of each
reagent was 10 μL. The plate was then incubated for 3 h
at room temperature. Without a washing step, 25 μL of
80 μg/mL AlphaScreen streptavidin-coated donor beads
were added. The reaction mixture was incubated in the
dark for another 30 min at room temperature, and the
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reader (BMG LABTECH, Ortenberg, Germany) using
the AlphaLISA mode (excitation wavelength of 680 nm
and emission detection set to 615 nm). Background sig-
nals obtained from PBS were subtracted from the mea-
sured signals.
The animal model of pulmonary fibrosis
All animal experiments were approved by the Tohoku
University Animal Experiment Ethics Committee and
performed in accordance with the Regulations for Animal
Experiments and Related Activities at Tohoku University.
Seven- to 8-week-old male C57BL/6 mice were used
in our experiments. C57BL/6 mice were purchased from
CLEA Japan (Yokohama, Japan). All mice were housed
in a specific pathogen-free facility and maintained under
constant temperature (24 °C), humidity (40 %), and light
cycle (8:00 A.M. to 8:00 P.M.), with food and water pro-
vided ad libitum. To induce pulmonary fibrosis, mice
were treated intratracheally with bleomycin hydrochlor-
ide (Nippon Kayaku, Tokyo, Japan) on day 0 as described
in our previous study [19]. Briefly, mice were anesthe-
tized with ketamine via intraperitoneal injection and
were then injected with 0.04 mg of bleomycin hydro-
chloride in 100 μl of saline through a 27G needle
inserted between the cartilaginous rings of the trachea.
Circulating blood was harvested 7, 14 or 28 days after
instillation. Collected blood was incubated at room
temperature for 1 h and centrifuged for 15 min at
1500 g at 4 °C. The serum was transferred to a new tube
and centrifuged again for 30 min at 2500 g at 4 °C to re-
move cells and debris. The clarified serum was trans-
ferred for further examination.
Subjects and specimens
This study was approved by the ethics committees at
Tohoku University School of Medicine, Japanese Red
Cross Ishinomaki Hospital and Hikarigaoka Spellman
Hospital. All subjects gave written informed consent.
This study is registered with UMIN-CTR, number
UMIN000017403.
Human peripheral blood was obtained from patients
or healthy volunteers at Japanese Red Cross Ishinomaki
Hospital (Ishinomaki, Japan) or at Hikarigaoka Spellman
Hospital (Sendai, Japan). Serum was obtained by centri-
fuging these specimens, aliquoted, and stored at −80 °C
until used in analyses of serum EV. Forty-one patients
with idiopathic pulmonary fibrosis (IPF) and 21 healthy
controls were included (Table 3). Diagnoses were made
according to the American Thoracic Society (ATS)/
European Respiratory Society (ERS) statement based on
clinical evaluation, high-resolution computed tomography,
histology, and laboratory findings [20]. Emphysematous
lesions were detected by CT and evaluated with GoddardLAA score [21]. The patients whose Goddard LAA score
is ≥1 were considered as having emphysema. The expert
clinicians who analysed the information were blinded to
the diagnoses associated with the experimental laboratory
tests. Usual interstitial pneumonia was confirmed by
surgical biopsy in 15 of the IPF patients (Table 3). The
patients were recruited at the time of diagnosis. The col-
lection of blood samples and pulmonary function tests
were performed at entry. IPF patients were followed for
30 months except in cases of death or failure to visit the
hospital. Survival status was obtained from visits to the
hospitals and telephone interviews. During the follow-up
periods, the patients received pulmonary function evalua-
tions 6 months after enrolment.
Preparation of EVs from mouse or human serum samples
Mouse or human serum samples were centrifuged at
10,000 g for 10 min to remove cells and debris. Subse-
quently, we extracted EVs from serum using a commer-
cial extracting reagent (Total Exosome Isolation from
serum, Thermo Fisher Scientific) as previously described
[22]. Briefly, we mixed 250 μL of centrifuged serum with
50 μL of an extracting reagent. The samples were incu-
bated at 4 °C for 30 min and then centrifuged at room
temperature at 10,000 g for 10 min. The supernatant
was discarded and the EV pellet was resuspended in
100 μL of PBS. The EV suspension was used for further
examination.
Extraction of serum EV RNA and synthesis of cDNA
Total RNA was extracted from serum EV using a
miRNeasy Mini Kit (QIAGEN, Hilden, Germany).
Synthetic C. elegans miR-39 (QIAGEN) was added to
samples of the serum EV suspension to control for
variations during the preparation of total RNA. The
miScript II RT Kit was used for reverse transcription
of microRNAs into cDNA.
MicroRNA PCR array in mouse serum EVs
The Mouse Serum miScript miRNA PCR Array (QIAGEN,
MIMM-106Z) was used according to the manufacturer’s
instructions for the comprehensive analyses of the expres-
sion levels of the microRNAs in the serum EV in a mouse
model of pulmonary fibrosis. Briefly, template cDNA that
had been synthesized from the mouse serum EV RNA was
added to each well of the miScript miRNA PCR array plate.
The plate was placed on the real-time cycler (StepOne
Plus, Thermo Fisher Scientific) and run. The data were
analysed using the web-based miScript miRNA PCR Array
data analysis tool (QIAGEN). MicroRNAs were considered
not detectable when Ct > 35. We also excluded the micro-
RNAs for which the Ct > 30 in either group for further
analyses on the basis that this indicated that the ex-
pression level was relatively low, which could cause
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Ct value (target microRNA Ct–cel-miR-39 Ct) in each
sample was calculated. The average of the delta Ct
values in each sample group was then calculated and
used to analyse the fold-changes of serum EV micro-
RNAs compared with non-treated controls. The ex-
pression levels of microRNAs were normalized by
dividing them by the amount of EVs in each serum
EV sample, as determined by the ExoScreen assay. To
control the false discovery rate for multiple compari-
sons, the Benjamini-Hochberg procedure was used
[23]. The q-value for the fold-change for selecting the
candidate microRNAs was less than 0.05.
Quantification of microRNAs in serum EVs
The microRNAs were quantified by real-time PCR using
the miScript Primer Assay (QIAGEN). The real-time
RT-PCR detection of the C. elegans miR-39 was also per-
formed for the normalization of the real-time RT-PCR
results of the endogenous microRNAs in the sample.
This procedure corrects for variations during the RNA
preparation, cDNA synthesis, and real-time PCR. To de-
termine the copy numbers of human miR-21-5p in the
serum samples, standard curves were prepared using
serial dilutions of synthetic human miR-21-5p (Bioneer,
Daejeon, Korea). The relative amount of the spiked cel-
miR-39 in each sample was calculated using the serially
diluted standard samples. This value was used for
normalization between samples. The formula for this
calculation is as follows: (The normalized amount of
miR-21-5p or miR-155-5p in sample X) = (the pre-
normalized amount of the microRNA in sample X) ×
(the amount of cel-miR-39 in the reference sample/the
amount of cel-miR-39 in sample X). The reference sam-
ple was one of the non-treated control samples for
mouse study or one of the IPF patient samples (the sam-
ple of IPF patient #1) for human study, respectively. The
expression levels of the microRNAs were normalized by
dividing them by the amount of EVs in each serum EV
sample, as determined by the ExoScreen.
Statistical analysis
The statistical analysis was performed using JMP Pro
11.0 (SAS Institute Inc., Cary, NC). In the animal experi-
ments, the data are presented as the means ± SEM
unless otherwise indicated. The Kruskal-Wallis test
was used for multiple comparisons, and p < 0.05 was
taken to represent statistical significance. We used
the Benjamini-Hochberg procedure [23] to control the
false discovery rate for multiple comparisons for the
microRNA PCR array analyses. The q-value for the
fold-change for selecting the candidate microRNAs
was less than 0.05. In the clinical setting, the data are
presented as the medians (IQR). The differences inthe distribution of the categorical data between two
groups were analysed using the Fisher exact test. The
differences in continuous data between two groups
were analysed using the Mann-Whitney U test. Corre-
lations between miR-21-5p and other clinical variables
were calculated using the Spearman rank correlation.
In the correlation analysis of the baseline characteris-
tics, the Cox proportional hazards model was used to
determine the effect of various factors on mortality in
IPF patients. These results are expressed as hazard ra-
tios for death among those who had a factor of inter-
est compared with those who did not have the factor.
We calculated the median values for the normalized
or non-normalized serum EV miR-21-5p levels in the
41 IPF patients. These values were determined to be
2.1 copies/SI or 1.25 × 107 copies/mL, respectively.
We divided the 41 IPF patients into the following
two groups: those above and those below the median
value. We also divided the IPF patients into the top-
quartile versus the remaining subjects for the following
analysis. Survival was evaluated using the Kaplan-Meier
approach, and the differences in survival between two
groups were compared using log-rank tests. A value
of P < 0.05 was considered to indicate statistical significance.
Results
MicroRNA expression profiling revealed an increase in
certain microRNAs, including miR-21-5p, in the serum
EVs during experimental lung fibrosis in mice
To identify the serum EV microRNAs that could serve
as biomarkers for fibrotic lung diseases, we first utilized
a mouse bleomycin-induced lung fibrosis model to
investigate the differences in the expression of serum
EV microRNAs compared to controls. We used the
microRNA-expression profiles derived from the serum
EVs rather than those from the total serum because
previous reports [24, 25] and our pilot study data
(Additional file 1: Figure S1) showed that analysing
the microRNAs from the EV-rich serum fraction im-
proved the reproducibility compared to the analysis of
whole serum. We assumed that the amount of EVs
was likely to influence the total amount of the EV
microRNAs in the serum and therefore normalized
the expression of the microRNAs by dividing these
values by the amounts of the EVs. To analyse the EV
quantities in the mouse serum and human samples,
we utilized ExoScreen, which was recently introduced
as a tool to investigate the EV levels and to profile
the EV surface proteins in human samples [18]. We
confirmed that ExoScreen successfully quantified the
levels of the CD9-positive pan-EVs in both the cell
culture supernatants and mouse serum samples, as
previously reported for human samples [18] (Fig. 1a, b).
We examined the changes in the levels of CD9-positive
Fig. 1 Circulating EVs increased during the acute phase of the experimental bleomycin-induced lung fibrosis model. a Detection of mouse
CD9-positive pan-EVs by ExoScreen. Correlation between ExoScreen measurements for CD9-positive pan-EVs and EV protein concentration
in a dilution series. EVs were purified from a mouse lung cancer cell line (Lewis lung carcinoma (LLC, left)) or a mouse mesenchymal cell line
(KUM-10, right). Error bars are SEM; n = 3 for each condition. b Detection of circulating EVs in mouse sera. Correlation between ExoScreen
measurements for CD9-positive pan-EVs and serum volume in a dilution series. Error bars are SEM; n= 3 for each condition. c Serum levels of CD9-positive
pan-EVs in an experimental BLM-induced lung fibrosis model. Two microliters of serum from each mouse were used for the detection of EVs by ExoScreen.
Note that the levels of pan-EVs were significantly higher in sera from mice at 7 days compared with those in non-treated (NT) mice. Error bars are SEM
(n= 9 for each time point). The data were assessed for significance using the Kruskal-wallis test for multiple comparisons. *, p< 0.05 vs. NT mice
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bleomycin-induced lung fibrosis. The levels of serum EVs
were significantly increased on day 7 after administration
relative to those in the untreated mice and returned to the
basal levels on days 14 and 28 (Fig. 1c).
To profile the changes in the microRNA expression in
the serum EVs from the bleomycin-induced lung fibrosis
model (histological analyses are shown in Additional
file 1: Figure S2 [26]), we isolated the total RNA from the
mouse serum EVs and performed quantitative real-time
PCR array analyses (n = 3 for each group). The full Ct
dataset corresponding to mouse microRNA PCR array
data is provided as the online Additional file 2 (The full Ct
dataset of mouse microRNA PCR array data.xlsx). We
have also provided tables that show the average Ct values,
including cel-miR-39 (spiked control), for each sample
group (Additional file 1: Table S1), the average of the
delta Ct values (target microRNA Ct–cel-miR-39
(spiked control) Ct) (Additional file 1: Table S2) andthe pre-normalized fold-changes of serum EV micro-
RNAs (Additional file 1: Table S3) in addition to the
post-normalized fold-changes generated by dividing
the pre-normalization values by the EV amounts in
the serum samples (Additional file 1: Table S4) in the
bleomycin-induced lung fibrosis model. We also ex-
amined the Ct values for miR-451a and miR-23a-3p to
calculate a delta Ct value (miR-23a-3p - miR-451a),
which is a previously reported indicator for erythro-
cyte miRNA contamination [27]. The delta Ct values
(miR-23a-3p–miR-451a) for all of the mouse serum
EV RNA samples used for the microRNA PCR array
were less than five (Additional file 1: Table S5), which
indicated that erythrocyte miRNA contamination was
not significant in these samples. The PCR array ana-
lyses revealed that distinct microRNAs in the serum
EVs significantly increased at each time point during
the progression of lung fibrosis in the mice (Fig. 2). The
fold-changes of the serum EV microRNAs that have been
Fig. 2 The microRNAs in the serum EVs increased significantly during
experimental bleomycin-induced lung injury in mice. Volcano plots
show the fold changes in the serum EV microRNAs compared with the
non-treated controls in the bleomycin-induced lung fibrosis model at
day 7 (a), day 14 (b) and day 28 (c) after administration of bleomycin.
The horizontal dotted line indicates q = 0.05. The vertical dotted lines
indicate fold changes = 2 or 0.5. The dots for miR-21-5p are indicated
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brosis are shown in Table 1. Among the significantly in-
creased microRNAs, miR-21-5p and miR-155-5p increased
compared with the non-treated mice at every time pointthroughout the progression of the lung fibrosis (Table 2).
Thus, these microRNAs could be considered as candidate
biomarkers for lung fibrotic diseases.
Then, we performed conventional quantitative real-
time PCR to examine and confirm the changes in the ex-
pression of EV miR-21-5p and miR-155-5p using a larger
number of samples (n = 9) for each time point. The rela-
tive expression levels of these microRNAs were also nor-
malized by dividing them by the EV amounts in the
serum samples. The PCR analysis confirmed that EV
miR-21-5p was significantly upregulated in the acute
phase (at day 7) and in the later chronic/fibrotic phase
(at days 14 and 28) (Fig. 3a). The levels of EV miR-155-
5p were significantly increased in the acute phase (at day
7) but returned to the basal level in the chronic/fibrotic
phase (Fig. 3b). These results showed that distinct
microRNAs in the serum EVs increased over the course
of the experimental lung fibrosis and that miR-21-5p, in
particular, was upregulated significantly in both the
acute phase and the chronic/fibrotic phase. This result
suggested that serum EV miR-21-5p represents a likely
candidate biomarker for fibrotic lung diseases, including
IPF.
Serum EV MiR-21-5p levels were elevated in IPF patients
Based on the results from the mouse lung fibrosis
model, we hypothesized that the serum levels of EV
miR-21-5p may be clinically associated with IPF. To test
this hypothesis, we analysed the correlations between
the serum EV miR-21-5p level and the changes in pul-
monary function and survival in IPF patients.
A total of 41 IPF patients were enrolled in the pro-
spective cohort study. The baseline characteristics of the
study participants (21 healthy controls and 41 IPF pa-
tients) are shown in Table 3.
We measured the relative amounts of CD9-positive
pan-EVs in the human serum samples using ExoScreen,
in which the signal intensity (SI) value is relative to the
total EV level [16]. Our pilot examination showed that
the total RNA yields isolated from the serum EVs
showed good correlation and regression with the relative
levels of the serum CD9-positive EVs (signal intensities
(SIs) for CD9 positive EVs) (Additional file 1: Figure S3).
There was no significant difference in the total serum
EVs between control and IPF subjects despite consider-
able variation even within the same subject groups
(Fig. 4a). Subsequently, we evaluated the expression
levels (copy numbers) of miR-21-5p contained in the
EVs isolated from 1 mL of serum (miR-21-5p copy num-
ber/mL) (Fig. 4b). The levels of serum CD9-positive EVs
were not significantly influenced by age or smoking his-
tory in our study subjects (Additional file 1: Figure S4).
The expression levels of miR-21-5p in the EVs from
1 mL of serum were significantly greater in the IPF
Table 1 The fold-changes of the serum EV microRNAs that had been reported to be associated with the pathogenesis of lung fibro-
sis in the bleomycin-induced lung fibrosis model compared with the non-treated controls
Name Day 7 Day 14 Day 28 Reference
Fold change q value Fold change q value Fold change q value
Upregulated microRNAs in lung fibrosis
miR-21-5p 9.29* 0.003 5.77* 0.036 7.97* 0.001 [19, 37–39]
miR-96-5p ND ND ND [42]
miR-145a-5p 0.68 0.715 2.35 0.647 0.81 0.554 [43]
miR-155-5p 4.28* 0.009 3.26* 0.039 6.37* 0.001 [44]
miR-195a-5p 1.79 0.314 1.40 0.976 1.13 0.828 [45]
Downregulated microRNAs in lung fibrosis
miR-17-3p 12.33* 0.022 2.54 0.705 2.12 0.878 [46]
miR-17-5p 0.91 0.724 1.81 0.713 0.55 0.465 [46]
miR-18a-5p 1.90 0.375 2.59 0.622 1.46 0.920 [46]
miR-19a-3p 4.10* 0.008 2.51 0.059 1.99 0.199 [46]
miR-20a-5p 1.40 0.508 1.91 0.804 0.56 0.498 [46]
miR-29a-3p 1.81 0.333 1.55 0.805 0.52 0.451 [47]
miR-30d-5p 1.61 0.359 1.74 0.701 1.33 0.922 [48, 49]
miR-92a-3p 0.71 0.918 1.68 0.701 1.41 0.855 [46, 48]
miR-200a-3p 4.23 0.085 1.91 0.717 4.58 0.388 [50]
miR-200b-3p 4.29 0.159 1.20 0.515 2.55 0.546 [50]
miR-200c-3pa 3.41 0.112 3.03 0.797 2.55 0.554 [19, 50]
ND not detected (Ct > 35)
*q value < 0.05 compared with non-treated control
amicroRNAs that had Ct > 30 in either group, which indicated that the expression levels were relatively low and could cause greater variations in the fold-change results
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interested in the net changes of miR-21-5p in the serum
EVs, we then normalized the expression levels of the
serum EV miR-21-5p by dividing them by the EV amount
in each serum sample (miR-21-5p copy number/signalTable 2 Serum EV microRNAs that showed a significant* increase in
non-treated controls













The expression levels of microRNAs were normalized to the amount of EVs in the m
indicating that the relative expression levels of these microRNAs were sufficiently h
and miR-155-5p (indicated by boldface) were significantly increased at every measu
*q value < 0.05 compared with non-treated control. The q value (false discovery rateintensity for CD9-positive pan-EVs). The expression levels
of the normalized serum EV miR-21-5p were also signifi-
cantly greater in the IPF subjects than in controls (Fig. 4c).
We also examined the expression levels of the normalized
serum EV miR-21-5p in a set of patients with COPD,the bleomycin-induced lung fibrosis model compared with






ouse serum samples. The Ct values of these microRNAs were less than 30
igh to evaluate for fold-changes without excessive variation. Both miR-21-5p
red time point during the 28 days after bleomycin administration
) was calculated by the Benjamini-Hochberg procedure
Fig. 3 Increase of miR-21-5p and miR-155-5p in serum EVs during experimental bleomycin-induced lung injury. a, b Relative expression levels of
both miR-21-5p (a) and miR-155-5p (b) are shown compared with non-treated control. The expression levels of microRNAs were normalized by
the amount of EVs in the mouse serum samples. Error bars are SEM (n = 9 for each time point). The data were assessed for significance by
Kruskal-wallis tests for multiple comparisons. *, p < 0.05 vs. non-treated control mice (NT)
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disease (Additional file 1: Table S6). There were no signifi-
cant differences in the total serum EVs among control,
COPD and IPF subjects (Additional file 1: Figure S5a).
The expression levels of miR-21-5p in the EVs from 1 mL
of serum in the COPD subjects were not significantly dif-
ferent from the controls but were significantly lower than
those of the IPF subjects (Additional file 1: Figure S5b).
The expression levels of the normalized serum EV miR-
21-5p were also not significantly different from the con-
trols but were significantly lower than those of the IPFTable 3 The baseline characteristics of the healthy control
subjects and the enrolled IPF patients
Control (n = 21) IPF (n = 41)
Sex, male, n (%) 16 (76) 32 (78)
Age, median (IQR) 69 (66–73) 72 (68–80)
Surgical lung biopsy undergo, n (%) N.A. 15 (36)
Baseline % predicted VC, median (IQR) 109 (100–120) 81 (67–93)
Emphysematous lesion detected
by CT, n (%) a
N.A. 4 (10)
Biomarker, median (IQR)
KL-6 N.A. 739 (557–1320)
SP-D N.A. 207 (142–303)
LDH N.A. 208 (183–247)
Smoking history
Yes, n (%) 17 (80) 34 (82)
Therapy, n (%) N.A.
No treatment N.A. 24 (58)
Pirfenidone N.A. 10 (24)
Prednisolone N.A. 8 (19)
Cyclosporine A N.A. 2 (4)
The data are expressed as the median values (IQR) or n (%)
N.A. not acquired, VC vital capacity, KL-6 Krebs von den Lungen-6, SP-D
surfactant protein D
a Goddard LAA score is ≥1subjects (Additional file 1: Figure S5c). There were no sig-
nificant differences in the levels of the normalized serum
EV miR-21-5p among the various GOLD stages in the
COPD patients (Additional file 1: Figure S5d) and no sig-
nificant correlations between the levels of serum EV miR-
21-5p and severity of airway obstruction (Additional file 1:
Figure S5e, f). Because the normalization step of dividing
the expression levels by the EV amount improved variabil-
ity of the measurements in the healthy control group (co-
efficient of variance; non-normalized levels of miR-21-5p:
0.755, normalized levels of miR-21-5p: 0.60), we used the
normalized expression levels of serum EV miR-21-5p for
the first of our subsequent analyses.
During the 30-month follow-up period, 11 patients
died and nine patients were censored on the basis of fail-
ure to visit the hospital. We evaluated the correlations
between the levels of serum EV miR-21-5p and the clin-
ical parameters (Table 4) of the IPF subjects at the time
of enrolment. The serum EV miR-21-5p levels were cor-
related with the rate of decline in the percent-predicted
VC per 6 months in the IPF subjects (Table 4).
Serum EV miR-21-5p is a predictive biomarker for
mortality in IPF patients
We calculated the hazard ratio (HR) using the Cox
proportional hazards model to evaluate the association
between the risk of death and clinical parameters, in-
cluding serum EV miR-21-5p. In the univariate mortality
analysis, age (HR, 1.09, 95 % CI, 1.001–1.20; p = 0.04)
and EV miR-21-5p (HR, 1.15, 95 % CI, 1.04–1.25;
p = 0.007) were associated with the risk of death
during the following 30 months (Table 5). In the multi-
variate mortality analysis, EV miR-21-5p was still inde-
pendently significant (EV miR-21-5p: HR, 1.12, 95 % CI,
1.003–1.24; p = 0.04) even after the adjustment for other
variables. Moreover, we demonstrated that the association
between miR-21-5p and mortality was significant even
after adjusting for gender, KL-6, %VC and age (Table 6).
Fig. 4 Serum EV miR-21-5p levels adjusted for the serum EV levels
are increased in IPF patients. a The relative levels of human serum
CD9-positive pan-EVs in healthy control subjects and IPF patients
were determined using ExoScreen as signal intensities. b The
expression levels of EV miR-21-5p in EVs isolated from 1 mL serum were
examined by quantitative RT-PCR. c The expression of EV miR-21-5p
normalized by dividing it by the relative EV amount is shown as
the copy number of miR-21-5p divided by the signal intensity
for CD9-positive pan-EVs in the serum samples. Differences between
the groups were analysed using the Mann-Whitney U test
Table 4 The relationships between the normalized levels of EV
miR-21-5p and the clinical variables in the 41 IPF patients
miR-21-5p (copies/SI)
rs P




Rate of decline in % predicted VC over 6 months 0.56 <0.001
rs: Spearman rank correlation coefficient. The correlations were calculated
using the Spearman rank correlation test
Bold denotes p < 0.05
VC vital capacity, DLco carbon monoxide diffusing capacity, KL-6 Krebs von
den Lungen-6, SP-D surfactant protein D
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miR-21-5p is a predictive biomarker for IPF prognoses.
We then divided the IPF patients into two groups,
those above and those below the median level of EV
miR-21-5p (2.1 copies/SI) and performed a Kaplan-
Meier analysis to investigate the difference between the
survival curves of the patients with higher and lower
serum EV miR-21-5p levels at the time of enrolment.
The characteristics of each group are shown in Table 7.The proportion of males and the baseline KL-6 signifi-
cantly differed between the two groups. As shown in
Table 5, neither sex nor KL-6 was associated with the
mortality during the 30-month period. We also exam-
ined whether there were differences between the blood
cell counts of the patients with higher and lower levels
of serum EV miR-21-5p. There were no significant
differences in the numbers of the white blood cells,
red blood cells, platelets, neutrophils, lymphocytes,
monocytes, eosinophils or basophils (Additional file 1:
Table S7). We also investigated whether there were
correlations between the levels of EV miR-21-5p and
the numbers of each type of blood cells and showed
that there were no significant correlations between
the levels of EV miR-21-5p and the blood cell counts
(Additional file 1: Figure S6). There was no sig-
nificant difference in the number of censored patients
between the higher and lower groups (five vs. four
patients, respectively). The Kaplan-Meier analysis
showed that the survival of the patients with higher
serum EV miR-21-5p levels was significantly worse
than that of the patients with lower EV miR-21-5p
levels. Nine (42 %) of the patients with higher base-
line serum EV miR-21-5p levels died, whereas two
(10 %) of the patients with lower EV miR-21-5p levels
died during the 30-month follow-up period (Fig. 5a).
We also performed the Kaplan-Meier analysis be-
tween the group of ten patients with levels of EV
miR-21 that were in the top quartile (more than four
copies/SI) and the group of 31 patients for whom the
levels of EV miR-21 were less than four copies/SI
(Fig. 5b). This analysis also clearly showed that the
survival of the top quartile group was worse than that
of the group with the lower levels of EV miR-21.
These analyses clearly showed that the survival of the
patients with high levels of serum EV miR-21 was
significantly worse than that of the patients with low
levels of serum EV miR-21.
Table 5 Univariate and multivariate Cox hazards model analyses for mortality during the 30-month follow-up period in the IPF
patients
Univariate Multivariate
HR (95 % CI) P value HR (95 % CI) P value
Sex
Male 0.60 (0.17–2.78) 0.48
Female 1.64 (0.35–5.75) 0.48
Age 1.09 (1.001–1.20)b 0.04 1.04 (0.95–1.16) 0.31
% predicted VC 0.98 (0.95–1.01)b 0.31
Emphysematous lesion detected by CT 2.20 (0.33–8.06) 0.35
Rate (%) of decline in VC per 6 months 1.04 (0.98–1.09)b 0.11
KL-6 0.99 (0.99–1.00)b 0.85
SP-D 1.00 (0.99–1.00)b 0.41
LDH 0.99 (0.97–1.00)b 0.23
miR-21-5p (copies/SI)a (per one copy/SI) 1.15 (1.04–1.25)b 0.007 1.12 (1.003–1.24) 0.04
CD9-positive EVs (×106 SI/mL) (per 1 ×106 SI/mL) 0.89 (0.75–1.02)b 0.10
Bold represents p < 0.05
HR hazard ratio, CI confidence interval, VC vital capacity, KL-6 Krebs von den Lungen-6, SP-D, surfactant protein D
alevels of serum EV miR-21-5p adjusted for the EV content in the serum samples
bA unit hazard ratio (hazard ratio per one unit change in each regressor) is shown
Table 7 Characteristics of the two groups into which IPF patients
were divided according to the median of the normalized levels of
serum EV miR-21-5p
Normalized miR-21-5p (copies/SI) P value
<2.1 ≥2.1
(n = 20) (n = 21)
Age, yr 71 (65–77) 75 (71–81) 0.15
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amount of each serum sample in the correlation between
the non-normalized levels of Serum EV MiR-21-5p and
clinical parameters, risk of death and survival
We also performed an analysis of the correlation be-
tween the non-normalized EV miR-21-5p copy numbers
and the clinical parameters as well as their association
with the risk of death and Kaplan-Meier analysis. The
levels of the non-normalized EV miR-21-5p copy num-
bers in the serum were also correlated with the rate of
decline in percent-predicted VC per 6 months and the
levels of serum SP-D (Additional file 1: Table S8). The
levels of the non-normalized miR-21-5p copy numbers
were also associated with the risk of death during the
following 30 months (Additional file 1: Table S9). How-
ever, the Kaplan-Meier analysis showed that there wasTable 6 The association between miR-21-5p of and mortality in
IPF patients during 30 months using Univariate Cox Hazard
model analyses with adjustment for each of the four parameters
The factor for adjustment Univariate
HR (95 % CI)a P value
Sex 1.16 (1.04–1.27) 0.008
Age 1.12 (1.003–1.24) 0.04
Emphysematous lesion detected by CT 1.19 (1.04–1.46) 0.01
KL-6 1.45 (1.15–1.83) 0.002
% predicted VC 1.16 (1.04–1.29) 0.01
Bold represents p < 0.05
HR hazard ratio, CI confidence interval, KL-6 Krebs von den Lungen-6 VC
vital capacity
aA unit hazard ratio (hazard ratio per one copy/SI in normalized serum EV miR-
21-5p) is shownno significant difference between the survival curves for
the patients with serum EV non-normalized miR-21-5p
copy numbers that were higher versus lower than the
median (Additional file 1: Table S10 and Figure S7a).
We also performed the Kaplan-Meier analysis to com-
pare the group of 10 patients with levels of EV miR-21
in the top quartile (more than 1.75 × 107 copies/mL)
and the group of 31 patients in whom the levels of EVSex, male, n (%) 19 (95) 13 (61) 0.02
Smoking history
Yes, n (%) 18 (90) 16 (76) 0.4
Baseline VC (%) 78 (69–104) 81 (62–91) 0.48
Emphysematous
lesion detected
by CT, n (%)
2 (10) 2 (10) 0.96
KL-6 645 (540–982) 1040 (706–1921) 0.04
SP-D 211 (141–277) 202 (140–320) 0.77
LDH 207 (183–215) 227 (177–280) 0.18
The data are expressed as n (%) or median (IQR). The differences in age,
% VC, or other serum markers between the two groups were analysed by
the Mann-Whitney U test. The comparison of gender, smoking history and
emphysema between the two groups was analysed using the Fisher
exact test
Bold represents p < 0.05
VC vital capacity, KL-6 Krebs von den Lungen-6, SP-D surfactant protein D
Fig. 5 Kaplan-Meier analysis grouped by the normalized levels of
the baseline serum EV miR-21-5p. a The solid line shows the group
of IPF patients that had baseline serum EV miR-21-5p levels above
the median level of EV miR-21-5p (2.1 copies/SI). The dashed line
shows the group of IPF patients that had baseline serum EV miR-21-5p
levels below the median level. The patients with the higher serum EV
miR-21-5p levels showed higher mortality during the 30-month
follow-up period (p = 0.01). b The solid line shows the group of IPF
patients that had the top-quartile baseline serum EV miR-21-5p levels
(≥4 copies/SI, n = 10). The dashed line shows the group of IPF patients
that had baseline serum EV miR-21-5p levels below four copies/
SI (n = 31). The patients who had serum EV miR-21-5p levels in
the top-quartile showed higher mortality during the 30-month
follow-up period (p = 0.0004). The dots represent cases that were
censored because of failure to visit the hospital. The entire
population (n = 41) contained nine censored patients
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of this analysis showed that there was a significant differ-
ence between the mortality rates for those in the top
quartile and the remaining subjects (Additional file 1:
Figure S7b). Then, we performed a receiver-operating-
characteristic (ROC) curve analysis to evaluate whether
the normalized miR-21-5p copy numbers were more pre-
dictive of death of IPF patients than the non-normalized
levels of the serum EV miR-21-5p (Additional file 1:
Figure S7c). The ROC analysis indicated that the area
under the curve (AUC) for the normalized levels of serum
EV miR-21-5p was 0.857 (95 % CI = 0.671–0.955). The
AUC for non-normalized levels of EV miR-21-5p was
lower (0.788; 95 % CI = 0.541–0.921) than that for normal-
ized levels, though the difference was not statisticallysignificant (P = 0.51). Altogether, although the non-
normalized EV miR-21-5p levels were also associated
with disease progression and the risk of death, our
data may suggest that the normalized serum EV miR-
21-5p levels might be the better predictor of mortality
in IPF patients.
The changes of levels of serum EV miR-21-5p after
treatment with Pirfenidone
In four out of the ten patients who were administered
Pirfenidone, we examined the levels of the serum EV
miR-21-5p in serum samples at 6 months and/or
12 months after registration and starting the treatment
(Additional file 1: Figure S8a). Although the sample size
is small, this examination showed a tendency for the
patients who seems to be responsive to Pirfenidone
(patients IPF 11 and 15) to have levels of serum EV
miR-21-5p that decreased or were maintained at low
levels at 6 and 12 months after starting the treatment
whereas the non-responder subjects (patients IPF 10 and
IPF 40) showed elevated levels of serum EV miR-21-5p
at 6 and/or 12 months (Additional file 1: Figure S8b).
These data suggest that levels of serum EV miR-21-5p
might be useful as biomarkers of treatment responsiveness.
Discussion
This study first demonstrated that the expression profile
of the microRNAs within the EVs in circulating blood
was significantly changed in a mouse bleomycin-induced
lung fibrosis model. Among the microRNAs that showed
an altered expression during lung fibrosis, serum EV
miR-21-5p expression was significantly upregulated in
both the acute phase and the later chronic/fibrotic
phase. In human subjects, the levels of serum EV miR-
21-5p after adjustment for the quantity of EVs were sig-
nificantly increased in the IPF patients. Moreover, the
baseline levels of the serum EV miR-21-5p were signifi-
cantly associated with the disease progression (the de-
cline in the percent-predicted VC) and mortality. This is
the first report to show that serum EV microRNA could
be a prognostic biomarker for IPF.
The circulating microRNAs in the whole serum have
been investigated by many researchers in their efforts to
identify useful candidate biomarkers for various diseases
[28, 29]. However, previous reports and the data from
our pilot study (Additional file 1: Figure S1) showed that
analysing the microRNAs from the EV-rich serum frac-
tion improved the reproducibility compared to the ana-
lysis of whole serum [24, 25]. Furthermore, there is no
clear consensus in the research community as to the ap-
propriate normalization control for microRNA expres-
sion profiling in serum samples. Moreover, because the
components of the EVs and their secretion dynamics
vary according to their cellular origin and environment
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analysis would reflect the condition of chronic diseases,
including fibrosis. Therefore, we focused on the EV-
associated microRNAs in the serum and examined their
changes during lung fibrosis. We hypothesized that the
mouse model could be suitable for a comprehensive
assay using PCR arrays due to its consistency and simple
background relative to human subjects, although the
mouse model does not ideally mimic the human disease.
Therefore, we first analysed the changes in serum EV
microRNAs in a mouse model of bleomycin-induced
lung fibrosis to identify candidate microRNAs for bio-
markers of fibrotic lung diseases. The PCR array assays
identified the EV microRNAs that were changed in the
mouse model. Among these microRNAs, additional
confirmatory quantitative PCR assays revealed that
miR-21-5p was upregulated in both the acute and
chronic/fibrotic phase, which suggested that only
serum EV miR-21-5p was changed throughout lung
fibrosis and could serve as a biomarker for human fi-
brotic lung diseases, including IPF. In the human sub-
jects, we examined the levels of miR-21-5p in the
serum EVs and the levels of EVs in serum samples.
Our data showed that, although there were no signifi-
cant differences among healthy controls, COPD pa-
tients and IPF patients, the EV levels in serum were
highly variable, even within the same subject group.
We assumed that the levels of EVs would influence
the levels of the microRNAs in the samples. More-
over, we were interested in the net change in the
microRNA content of the EVs, rather than the total
amount of the microRNA in the serum EV samples,
because the change in the content of individual spe-
cies, rather than the total content, reflects the condi-
tion of cells or tissues during disease. Therefore, we
then attempted to normalize the expression levels of
the serum EV miR-21-5p by dividing them by the EV
amount in each serum sample (miR-21-5p copy num-
ber/signal intensity for CD9-positive pan-EVs). This
normalization step also improved the variability in the
measurements in the healthy control group. On the
basis of these results, we used the normalized levels
of serum EV miR-21-5p for our initial analyses.
The correlation analyses between the serum EV miR-
21-5p and clinical parameters indicated that both normal-
ized and non-normalized serum EV miR-21-5p levels were
correlated with the rate of decline in the percent-
predicted VC over 6 months. Furthermore, we demon-
strated that the miR-21-5p baseline levels could predict
the mortality of IPF patients during the 30-month follow-
up period. Our data suggested that the levels of serum EV
miR-21-5p at baseline are predictive of long-term mortal-
ity in IPF patients and can also predict the short-term dis-
ease progression in terms of the decline in lung function.Two recent reports have analysed the expression of
microRNAs in the serum samples of IPF patients [31,
32]. These two reports showed that the miR-21-5p in
whole serum was increased in the IPF patients compared
to the healthy controls, which is consistent with our
findings from the serum EV microRNA analyses. How-
ever, in our prospective cohort study, we first clearly dem-
onstrated that the baseline levels of serum EV miR-21-5p
were significantly correlated with the disease progression
(a decrease in predicted % VC) and were associated with
mortality during the 30-month follow-up period. Our
study is the first report to suggest that the microRNA in
the serum EVs could be a promising candidate for a prog-
nostic biomarker in patients with IPF.
Our study has not elucidated the mechanism for the
increase in the serum EV miR-21-5p in IPF patients. Ac-
cumulating evidence has suggested that miR-21-5p plays
a vital role in various biological responses and patho-
logical processes [33–35]. A study that used miR-21
gene-targeted mice clearly showed that miR-21-5p tar-
geted tumour suppressor genes, including spry1, pten,
and pdcd4 [33]. The expression of miR-21-5p is also reg-
ulated at the post-transcriptional level by the TGF-β
family of proteins and their downstream signal transduc-
ers, the SMADs [36], which are key regulators in the
pathogenesis of fibrosis. Our previous reports and those
of others have shown that miR-21-5p is increased in
whole-lung samples from both bleomycin-induced
mouse models of lung fibrosis and human patients with
IPF [19, 37–39]. MiR-21-5p targets an inhibitory SMAD
called SMAD7, and administration of miR-21-5p anti-
sense probes attenuates the severity of the bleomycin-
induced fibrosis by blocking the positive feedback loop
of TGF-β signalling [38]. MiR-21-5p is also expressed in
lung epithelial cells, and increased miR-21-5p expression
was observed in the lungs of patients with IPF [19]. It is
possible that the increased levels of serum EV miR-21-
5p reflect the conditions of fibrotic lung diseases, includ-
ing IPF, in which TGF-β signalling is one of the most
relevant signalling pathways. However, miR-21-5p ex-
pression is also regulated by other factors that are in-
volved not only in fibrosis but also in cell proliferation
and inflammation. It is, therefore, likely that the reason
for the increases in the levels of serum EV miR-21-5p in
IPF patients is more complicated.
There are limitations to this study. First, the sample
size for the human study was relatively small. This may
explain why this study did not show that factors, includ-
ing male gender, were risk factors for death, although
these factors have been reported as independent risk fac-
tors for disease progression [40, 41]. To confirm our ob-
servation, another cohort study with a larger sample size
would be needed. Next, we isolated (or concentrated)
the EVs from the sera using a reagent (Total Exosome
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of EVs using Exoscreen and the microRNA expression
profiles, followed by the analyses of the microRNA ex-
pression profiles after normalization to the amount of
EVs. However, the isolation reagent contains polymers
that sequester the water molecules to force the less-
soluble components, such as vesicles, to be precipitated.
It is, therefore, possible that other vesicles, particles and
protein aggregates could have contaminated the precipi-
tate that contains the EVs. This isolation reagent may
therefore not be the ideal method for the isolation of
pure EVs. Exosomal biomarkers have the advantage of
being more specific and stable compared to other bio-
markers from the biological fluid. However, it will be
very important to increase the efforts to establish a stan-
dardized method for the isolation of pure EVs and the
microRNA inside these EVs for both disease prediction
and pathogenesis elucidation. Third, Exoscreen seems to
be a better available method to evaluate the amount of
EVs on the basis that we observed that the total yield of
RNA (mainly, small RNAs; Additional file 1: Figure S3)
isolated from the serum EVs showed a good correlation
with the relative levels of serum CD9-positive EVs (sig-
nal intensities (SIs) for CD9 positive EVs). However, it is
possible that the EVs for which the expression is low or
is downregulated in the pathological conditions may
cause discrepancy between signal intensities (SIs) for
CD9 positive EVs and the actual amount of EVs. Because
there is no established method to count the absolute
number of EVs or measure the absolute amount of EVs,
it is difficult to solve this possible discrepancy at the
present. We also think that it is also important to establish
the method to measure the absolute number or amount
of EVs in biological fluid samples for normalization. More-
over, to explore the method to count and isolate the
specific EVs originated form specific types of cells (for
example, epithelium or endothelium) or the cells under
pathological conditions is thought to be useful for both
establishing biomarkers and understanding pathogen-
esis of various diseases. Final, we first used the normal-
ized levels of serum EV miR-21-5p for our analyses
because we were interested in the net change in the
microRNA contents of the EVs. However, although this
normalization step improved the variability in the mea-
surements in the healthy control group and some of
the analysed results suggested that the normalization
might have improved the ability to predict the mortality
of the IPF patients (Additional file 1: Figure S7), it is
also true that the benefit of this normalization seems to
have been minimal in this study (Additional file 1:
Table S8 and S9). To confirm the benefit of the
normalization, another cohort study with a larger sam-
ple size and improvements in both the EV isolation and
EV measurement would be needed.Conclusions
Our comprehensive analysis of the expression of micro-
RNAs in serum EVs in a mouse lung fibrosis model re-
vealed miR-21-5p as a potential prognostic biomarker of
IPF. In our clinical studies, the levels of serum EV miR-
21-5p adjusted by the EV amount significantly predicted
both the disease progression and mortality. EV miR-21-
5p could be useful to distinguish patients in need of in-
tensive therapies, including novel therapies.
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